Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Treasury Shares (2022 - 2025)

Historic Treasury Shares for Lucid Diagnostics (LUCD) over the last 4 years, with Q3 2025 value amounting to $6.6 million.

  • Lucid Diagnostics' Treasury Shares rose 6893.76% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 6893.76%. This contributed to the annual value of $3.9 million for FY2024, which is 6673.97% up from last year.
  • Lucid Diagnostics' Treasury Shares amounted to $6.6 million in Q3 2025, which was up 6893.76% from $6.6 million recorded in Q2 2025.
  • Lucid Diagnostics' Treasury Shares' 5-year high stood at $6.6 million during Q1 2025, with a 5-year trough of $1.8 million in Q3 2023.
  • For the 4-year period, Lucid Diagnostics' Treasury Shares averaged around $3.4 million, with its median value being $2.3 million (2024).
  • In the last 5 years, Lucid Diagnostics' Treasury Shares plummeted by 1719.08% in 2023 and then skyrocketed by 18659.03% in 2025.
  • Lucid Diagnostics' Treasury Shares (Quarter) stood at $2.1 million in 2022, then grew by 11.76% to $2.3 million in 2023, then surged by 66.74% to $3.9 million in 2024, then skyrocketed by 68.94% to $6.6 million in 2025.
  • Its Treasury Shares stands at $6.6 million for Q3 2025, versus $6.6 million for Q2 2025 and $6.6 million for Q1 2025.